Figure S1. TP53 opposes EGFR in glioblastoma. (A) Kaplan-Meier overall survival curves of patients from the TCGA LGG + GBM cohort. Patients were separated based on the TP53 status. (B,C) Frequency analysis of somatic mutations (B) and copy number amplification (C) in glioblastomas grouped according to TP53 status. * Statistically significant p < 0.0001.
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